 |
|
Hormone Therapy and Ovarian Cancer
Lina Steinrud Mørch, MSc;
Ellen Løkkegaard, MD, PhD;
Anne Helms Andreasen, MSc;
Susanne Krüger-Kjær, MD, DrMSci;
Øjvind Lidegaard, MD, DrMSci
JAMA. 2009;302(3):298-305.
Context Studies have suggested an increased risk of ovarian cancer among women taking postmenopausal hormone therapy. Data are sparse on the differential effects of formulations, regimens, and routes of administration.
Objective To assess risk of ovarian cancer in perimenopausal and postmenopausal women receiving different hormone therapies.
Design and Setting Nationwide prospective cohort study including all Danish women aged 50 through 79 years from 1995 through 2005 through individual linkage to Danish national registers. Redeemed prescription data from the National Register of Medicinal Product Statistics provided individually updated exposure information. The National Cancer Register and Pathology Register provided ovarian cancer incidence data. Information on confounding factors and effect modifiers was from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates.
Participants A total of 909 946 women without hormone-sensitive cancer or bilateral oophorectomy.
Main Outcome Measure Ovarian cancer.
Results In an average of 8.0 years of follow-up (7.3 million women-years), 3068 incident ovarian cancers, of which 2681 were epithelial cancers, were detected. Compared with women who never took hormone therapy, current users of hormones had incidence rate ratios for all ovarian cancers of 1.38 (95% confidence interval [CI], 1.26-1.51) and 1.44 (95% CI, 1.30-1.58) for epithelial ovarian cancer. The risk declined with years since last use: 0 to 2 years, 1.22 (95% CI, 1.02-1.46); more than 2 to 4 years, 0.98 (95% CI, 0.75-1.28); more than 4 to 6 years, 0.72 (95% CI, 0.50-1.05), and more than 6 years, 0.63 (95% CI, 0.41-0.96). For current users the risk of ovarian cancer did not differ significantly with different hormone therapies or duration of use. The incidence rates in current and never users of hormones were 0.52 and 0.40 per 1000 years, respectively, ie, an absolute risk increase of 0.12 (95% CI, 0.01-0.17) per 1000 years. This approximates 1 extra ovarian cancer for roughly 8300 women taking hormone therapy each year.
Conclusion Regardless of the duration of use, the formulation, estrogen dose, regimen, progestin type, and route of administration, hormone therapy was associated with an increased risk of ovarian cancer.
Author Affiliations: Gynaecological Clinic, Rigshospitalet, Copenhagen University, Copenhagen (Ms Mørch and Dr Lidegaard); Gynaecological-Obstetrical Department, Hillerød Hospital, Copenhagen University, Copenhagen (Dr Løkkegaard); Research Center for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark (Mss Mørch and Andreasen), Glostrup; and Department of Virus, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Østerbro, Denmark (Dr Krüger-Kjær).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Hormone Therapy Use and Risk of Ovarian Cancer
Alastair H. MacLennan and Rodney Baber
JAMA. 2009;302(20):2203.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hormone Therapy Use and Risk of Ovarian Cancer
MacLennan and Baber
JAMA 2009;302:2203-2203.
FULL TEXT
Hormone Therapy and Risk for Ovarian Cancer
JWatch General 2009;2009:1-1.
FULL TEXT
All you need to read in the other general journals
BMJ 2009;339:b2918-b2918.
FULL TEXT
Menopausal HT and Ovarian Cancer: Causal Role Remains Unclear
JWatch Women's Health 2009;2009:1-1.
FULL TEXT
|
